Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren in nonsense-mutation Duchenne muscular dystrophy
NCT00264888Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2005
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ataluren in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Dystrophin expression at 28 days. Started Dec 2005; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT00264888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264888.